RMC No. 27-2026: Updated FDA List of VAT-Exempt Drugs for Cancer, Diabetes, Hypertension, and Other Illnesses

RMC No. 27-2026 updates the FDA-endorsed VAT-exempt drug list for cancer, diabetes, hypertension, kidney disease, mental illness, and more. Businesses selling covered medicines must immediately check whether their pharmacy, hospital, distribution, accounting, and point-of-sale systems reflect the updated VAT-exempt drug list endorsed by the Food and Drug Administration. RMC No. 27-2026 publishes the updated full […]

RMC No. 25-2025: FDA Updates to VAT-Exempt Medicines for Diabetes, Hypertension, High Cholesterol, and Mental Illness

RMC No. 25-2025 confirms FDA updates to VAT-exempt medicines for diabetes, hypertension, high cholesterol, and mental illness under TRAIN and CREATE. Businesses selling, purchasing, distributing, or accounting for medicines covered by the FDAโ€™s updated VAT-exempt list must immediately review their product master files, invoicing settings, and VAT treatment because the VAT exemption takes effect upon […]

RMC No. 34-2024: FDA Updates to VAT-Exempt Medicines for Cancer, Hypertension, and Mental Illness Under TRAIN and CREATE

RMC No. 34-2024 confirms FDA updates to VAT-exempt medicines for cancer, hypertension, and mental illness, with effect from FDA publication. Businesses selling medicines for cancer, hypertension, and mental illness must immediately check the latest Food and Drug Administration updates to the VAT-exempt product list because VAT exemption takes effect on the date the FDA publishes […]

RMC No. 72-2023: Updated VAT-Exempt Medicines List for Cancer, Diabetes, Hypertension and Other Conditions

RMC No. 72-2023 updates the VAT-exempt medicines list, affecting cancer, diabetes, hypertension and other medicines sold by healthcare businesses. Pharmacies, hospitals, clinics, medicine distributors, and VAT-registered healthcare businesses must immediately review whether their medicine master lists, point-of-sale systems, invoices, and tax coding reflect the latest FDA-endorsed updates to the VAT-exempt medicines list. RMC No. 72-2023 […]

RMC No. 124-2022: VAT-Exempt Medicines Updated for Cancer, Tuberculosis, Mental Illness, Diabetes, and Hypertension Under CREATE

RMC No. 124-2022 updates VAT-exempt medicines under CREATE for cancer, tuberculosis, mental illness, diabetes, and hypertension based on FDA publication. Businesses selling, importing, prescribing, dispensing, accounting for, or claiming VAT treatment on covered medicines must check the updated VAT-exempt medicine list immediately because the exemption applies based on the date the Food and Drug Administration […]

RMC No. 116-2022: Updated VAT-Exempt Medicines List for Hypertension, Diabetes, Kidney Disease, Mental Illness, Cancer, and Deleted COVID-19 Medicines

RMC No. 116-2022 updates the VAT-exempt medicines list under CREATE, adding certain chronic disease medicines and deleting some COVID-19 medicines. Pharmacies, hospitals, clinics, distributors, importers, and accounting teams handling medicines must immediately check whether their products remain VAT-exempt, newly qualify for VAT exemption, or have been removed from the VAT-exempt list. RMC No. 116-2022 confirms […]

RMC No. 68-2022: Updated VAT-Exempt Medicines List for Hypertension, Diabetes, Cancer, COVID-19 and Other Treatments

RMC No. 68-2022 updates the FDA-endorsed VAT-exempt medicines list under CREATE for key disease categories including COVID-19 and cancer. Pharmacies, hospitals, clinics, distributors, importers, and VAT-registered sellers of medicines must check whether their covered products are included in the updated VAT-exempt medicines list endorsed by the Food and Drug Administration, because qualifying medicines for hypertension, […]

RMC No. 56-2022: VAT-Exempt Medicines List Updated for Hypertension and COVID-19 Treatment Under CREATE Act

RMC No. 56-2022 updates the VAT-exempt medicines list for hypertension and COVID-19 treatment under the CREATE Act, requiring item-level VAT review. Pharmacies, hospitals, distributors, importers, clinics, and businesses selling or purchasing medicines for hypertension and COVID-19 treatment should immediately review their VAT treatment because RMC No. 56-2022 updates the List of VAT-Exempt Medicines under Republic […]

RMC No. 101-2020: Addendum to VAT-Exempt Drugs for Hypertension, Diabetes and High Cholesterol

RMC No. 101-2020 publishes the FDA addendum to VAT-exempt drugs for hypertension, diabetes, and high cholesterol under RA 11467. Businesses selling, purchasing, prescribing, distributing, or accounting for medicines for hypertension, diabetes, and high cholesterol must immediately check whether their drug databases, point-of-sale systems, invoices, tax coding, and VAT treatment reflect the expanded list of VAT-exempt […]

RMO No. 23-2020: ATRIG Processing for VAT-Exempt Imported Prescription Drugs and Medicines

RMO No. 23-2020 centralizes ATRIG processing for VAT-exempt imported prescription drugs and medicines and confirms key exemption dates. Importers, manufacturers, distributors, wholesalers, and retailers dealing in VAT-exempt prescription drugs and medicines must secure the proper Authority to Release Imported Goods before release of covered importations. RMO No. 23-2020 centralizes the processing of ATRIG applications for […]